The effect of empagliflozin (sodium–glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
The effect of empagliflozin (sodium–glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study ; volume:25 ; number:1 ; day:7 ; month:10 ; year:2024 ; pages:1-8 ; date:12.2024
BMC musculoskeletal disorders ; 25, Heft 1 (7.10.2024), 1-8, 12.2024
- Urheber
-
Tan, Jinmei
Guo, Aili
Zhang, Keqin
Jiang, Yanli
Liu, Huaning
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12891-024-07900-5
- URN
-
urn:nbn:de:101:1-2412242111363.863335553960
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tan, Jinmei
- Guo, Aili
- Zhang, Keqin
- Jiang, Yanli
- Liu, Huaning
- SpringerLink (Online service)
Ähnliche Objekte (12)
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
Effects of the sodium-glucose cotransporter 2 inhibitors Canagliflozin, Dapagliflozin and Empagliflozin on endothelial barrier dysfunction : An in-vitro study
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
Effects of the sodium-glucose cotransporter 2 inhibitors Canagliflozin, Dapagliflozin and Empagliflozin on endothelial barrier dysfunction : An in-vitro study
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
Effects of the sodium-glucose cotransporter 2 inhibitors Canagliflozin, Dapagliflozin and Empagliflozin on endothelial barrier dysfunction : An in-vitro study
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review